The UniCAR technology and all its variants demonstrated great therapeutic potential in vitro and in vivo against hematological malignancies and solid tumors, including AML cells expressing CD33 and CD123 antigens [1, 21, 173–175], CD19+ tumor cells [176], carcinoma cells expressing tumor-associated carbohydrate sialyl-Tn antigen carcinomas [177, 178], EGFR-expressing tumor cells [179, 180], CD98 or EGFR radioresistant head and neck squamous cell carcinoma cells [181], and prostate cancer cells overexpressing prostate stem cell antigen (PSCA) or PSMA [21, 182, 183]. Here, CD33 is linked to neoplasm.